Responses
Original research
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Compose a Response to This Article
Other responses
No responses have been published for this article.